(1-hexahydroazepinyl)(tricyclo[3.3.1.1^3,7]dec-1-yl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: (1-hexahydroazepinyl)(tricyclo[3.3.1.1^3,7]dec-1-yl)methanone
• 英文别名: ((hexahydroazepinyl)tricyclo[3.3.1.1^3,7]dec-1-yl)methanone；1-(1-Adamantylcarbonyl)azepane；1-adamantyl(azepan-1-yl)methanone
• 化学式: C₁₇H₂₇NO
• 分子量: 261.407
• InChiKey: XICGPKIYVIIEFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1-hexahydroazepinyl)(tricyclo[3.3.1.1^3,7]dec-1-yl)methanone 在 diborane(6) 作用下， 以 四氢呋喃 为溶剂， 以94%的产率得到1-Adamantan-1-ylmethyl-azepane
  参考文献：
  名称：

  Amines That Transport Protons across Bilayer Membranes:  Synthesis, Lysosomal Neutralization, and Two-Phase pK_a Values by NMR

  摘要：

  It is desirable to be able to control the pH of lysosomes. A collection of lipophilic, nitrogenous bases, designed to act as membrane-active, catalytic proton transfer agents, were prepared and their effective pK(a)s measured in a vigorously stirred, two-phase system. One phase was a phosphate buffer whose pH was varied over the range ca, 1-11. The other was an immiscible, deuterated organic solvent in which the compounds preferentially resided even when protonated. When chemical shift changes versus the pH of the buffer were plotted, clear pK(a) curves were generated that are relevant to transmembrane proton transfer behavior. The two-phase pK(a)s increased with increasing counterion lipophilicity and with increasing organic solvent polarity, The compounds were also tested for their ability to neutralize the acidity of lysosomes, a model for other acidic vesicles involved in drug sorting. The most successful of these, imidazole 6a, has > 100 times the neutralizing power of ammonia, a standard lysosomotropic amine, causing a 1.7 unit rise in lysosomal pH of RAW cells at 0.1 mM, compared to a 0.2 and 1.4 unit rise for ammonium chloride at 0.1 and 10 mM, respectively.

  DOI：

  10.1021/jo960367f
• 作为产物：
  描述：

  环己亚胺 、 金刚烷酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 (1-hexahydroazepinyl)(tricyclo[3.3.1.1^3,7]dec-1-yl)methanone
  参考文献：
  名称：

  COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES

  摘要：

  该发明涉及一种化妆品组合物及其前体。该组合物具有固体剂和液体剂，两者均为化妆品益处成分。在创新组合物中，固体剂在液体剂中的溶解性在三环十二碳酰胺的存在下得到增强。

  公开号：

  US20160008249A1

文献信息

• COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES
  申请人：Conopco, Inc., d/b/a UNILEVER

  公开号：US20160008249A1

  公开（公告）日：2016-01-14

  The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inventive compositions is enhanced in the presence of a tricyclodecane amide.

  该发明涉及一种化妆品组合物及其前体。该组合物具有固体剂和液体剂，两者均为化妆品益处成分。在创新组合物中，固体剂在液体剂中的溶解性在三环十二碳酰胺的存在下得到增强。
• [EN] PHOTOPROTECTIVE COMPOSITIONS WITH TRICYCLODECANE AMIDES<br/>[FR] COMPOSITIONS DE PHOTOPROTECTION CONTENANT DES TRICYCLODÉCANES AMIDES
  申请人：UNILEVER PLC

  公开号：WO2014139965A1

  公开（公告）日：2014-09-18

  A personal care photoprotective composition is provided having a UV-A and UV-B sunscreen in conjunction with a tricyclodecane amide. The tricyclodecane amide functions to boost UV-A, UV-B and SPF performance when the personal care composition is applied to skin or hair of the human body.

  提供一种个人护理光保护组合物，其中包含UV-A和UV-B防晒剂，以及三环十二烷酰胺。当该个人护理组合物被涂抹在人体皮肤或头发上时，三环十二烷酰胺能够增强UV-A、UV-B和SPF的性能。
• Pharmaceutical use of substituted amides
  申请人：Andersen Sune Henrik

  公开号：US20060111366A1

  公开（公告）日：2006-05-25

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文介绍了使用取代酰胺来调节11β-羟化甾体脱氢酶1型（11βHSD1）的活性以及将这些化合物用作制药组合物的方法。还介绍了一类新型的取代酰胺，它们在治疗中的应用、包含这些化合物的制药组合物以及它们在药物制剂制造中的应用。这些化合物是11βHSD1的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低活性糖皮质激素细胞内浓度的医学疾病。
• Amide Derivatives and Pharmaceutical Use Thereof
  申请人：Andersen Henrik Sune

  公开号：US20090264414A1

  公开（公告）日：2009-10-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟化类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为药物组分的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括含有这些化合物的药物组分以及它们在制造药物中的用途。这些化合物是调节剂，更具体地说是11βHSD1活性的抑制剂，可用于治疗、预防和/或预防一系列医学疾病，其中降低细胞内活性糖皮质激素的浓度是可取的。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。